{'fraction_non_alphanumeric': 0.05217691776088459, 'fraction_numerical': 0.025915687629578438, 'mean_word_length': 5.056485355648536, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
LATE TOXICITIES AND LONG‐TERM MONITORING IN CLASSICAL HODGKIN LYMPHOMA AND DIFFUSE LARGE B‐CELL LYMPHOMA SURVIVORS: A SERIES OF SYSTEMATIC REVIEWS OF THE FONDAZIONE ITALIANA LINFOMI

cancer. An elevated risk of second primary tumors from the use of radioactive iodine (RAI) therapy in TC patients, in particular in pediatric and young adult patients, may explain the elevated incidence of acute lymphoid leukaemias and hemolymphoiectic neoplasms overall. The present finding may help in designing surveillance programs for hemolymphopoietic cancers in TC patients and vice versa keeping into consideration the possibility of overdiagnosis of TC. neurologic and cognitive toxicity (n = 62), healthy lifestyles (n = 10). The optimal detection and monitoring was found out for: i) early left ventricular ejection fraction dysfunction, coronary artery disease, valvular heart disease; ii) secondary acute myeloid leukemias/ myelo-displastic syndromes and solid tumors; iii) metabolic syndrome, thyroid, gonadal, and mineral bone disorders; iv) peripheral neuropathy, fatigue, cognitive impairment, anxiety and depression. Fertility pres-ervation and correction of unhealthy lifestyles were also examined. Conclusion : The final documents could be a reasonable bridge from evidence to decision in order to improve the clinical practice and customize the general follow ‐ up approach of cHL and DLBCL survivors. France, Germany, Italy, and Spain was conducted. Patients were treated at second ‐ line (2L) or third ‐ line (3L) between January 2015 and December 2018. HRU including hospitalizations, length of stay (LoS), Intensive Care Unit (ICU) days, and EmergencyRoom(ER)visitswasassessedandstratifiedbypatients'R/ R status [primary refractory, relapsed without Stem Cell Transplant (SCT), or relapsed post SCT] and LoT. Baseline characteristics and induction regimens were summarized. HRU for induction or SCT was excluded. Results: Data on 725 and 309 R/R ALL patients who started 2L and 3L respectively were analyzed (Table 1). Sample size varied by outcome. Median ages were 53 years (2L) and 50 years (3L). The majority were male (2L: 72.1%; 3L: 64.1%), and about a quarter were Philadelphia ‐ positive (2L: 25.2%; 3L: 25.6%). 34.5% (2L) and 47.6% (3L) of patients were treated with new regimens (blinatumomab or inotuzu-mab). Over the duration of therapy (DoT) (2L: 7.7 months, 3L: 7.4 months), the percent of patients hospitalized ranged over varying R/R status from 27.1% to 39.7% (2L) and 27.4% to 47.6% (3L). For both 2L and 3L, relapsed patients post SCT had higher hospital and ER use compared to primary refractory and relapsed patients without SCT. Conclusions: HRU is substantial for R/R ALL. Relapsed patients post SCT had more hospitalizations and ER visits compared to other R/R ALL patients. There is a need for more effective therapies with po-tential to reduce HRU for R/R ALL.